Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Fallopian Tube Neoplasms 3Ovarian Neoplasms 2Triple Negative Breast Neoplasms 1Solitary Fibrous Tumor, Pleural 1Prostatic Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Fallopian Tube Mucinous Adenocarcinoma 1Carcinosarcoma 1Carcinoma, Endometrioid 1

Interventions

Carboplatin 13pembrolizumab 12Specimen Handling 9Paclitaxel 5Magnetic Resonance Spectroscopy 5Capecitabine 5Biopsy 5Nivolumab 4Cyclophosphamide 4sacituzumab govitecan 3Gemcitabine 3Fulvestrant 3olaparib 2fludarabine 2atezolizumab 2aldesleukin 2Taxes 2Letrozole 2Epirubicin 2Docetaxel 2Cisplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2zimberelimab 1veliparib 1trastuzumab deruxtecan 1toripalimab 1sintilimab 1pyrotinib 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × cediranib × 30 days × Clear all
NCT01116648 2026-05-28

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
155 enrolled 34 charts
BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡